PubMed Health⌕ Search

Biomedical subjects

E Reschini

Publications and source records attributed to E Reschini.

At least 55 records · Page 3Linked to original sources
PubMed1978

Spontaneous remission of Cushing syndrome after termination of pregnancy.

A 27-year-old women developed Cushing syndrome during pregnancy. The course of pregnancy was characterized by abnormally low urine and plasma estrogen levels despite the presence of a living fetus. The signs and symptoms of Cushing syndrome disappeared spontaneously within 2 months after delivery. Hormonal studies, however, suggested the presence of an adrenal tumor. An adrenocortical adenoma was found at surgery and removed.

Adenoma↗
PubMed1978

Comparison of placebo and bromocriptine in the treatment of patients with normoprolactinaemic amenorrhoea.

Fourteen women with normoprolactinaemic amenorrhoea were treated with bromocriptine (2.5 mg twice daily) for a period ranging from 4 to 17 weeks, while a matched group fo 19 amenorrhoeic women were treated with a placebo (one tablet twice daily) for 4 to 12 weeks. About half of the patients in both groups had at least one episode of vaginal bleeding during treatment. There was no clear difference in the menstrual and ovulatory pattern between placebo and bromocriptine groups.

Amenorrhea↗
PubMed1978

Suppression of puerperal lactation by metergoline.

Based on the known stimulatory effect of serotonin on prolactin secretion, a trial of suppression of puerperal lactation by a potent serotonin antagonist, metergoline, was carried out in 30 puerperal women who did not want to nurse. The drug was administered orally at the dose of 4 mg tid for 5 days to all subjects, starting between 24 and 72 hours from delivery. Lactation was either prevented or rapidly suppressed in all subjects. Rebound of lactation after the end of treatment was observed in 10% of cases. Metergoline administration was associated with a significant suppression of the plasma prolactin levels.

Depression, Chemical↗
PubMed1977

Failure of dopamine infusion to suppress the plasma prolactin response to sulpiride in normal and hyperprolactinemic subjects.

In eleven normal women dopamine infusion (5 microgram/Kg/min) significantly lowered plasma prolactin levels but failed to suppress the PRL response to sulpiride (10 or 100 mg i.v.), while the same dose of dopamine was effective in abolishing the PRL response to TRH (200 microgram i.v.). In four hyperprolactinemic women showing an impaired PRL response to sulpiride, dopamine infusion was effective both in lowering PRL circulating levels and in restoring an evident response to sulpiride. This finding suggests an impairment of endogenous dopamine activity in hyperprolactinemic amenorrhea.

Amenorrhea↗
PubMed1976

Inhibitory effect of somatostatin on dibutyryl cyclic AMP-induced insulin and growth hormone release in human subjects.

The effect of somatostatin on the responses of blood glucose, plasma immunoreactive insulin (IRI), growth hormone (GH), and free fatty acids (FFA) to the injection of dibutyryl cyclic AMP (DBC) was studied in six normal volunteers. DBC, when injected alone, induced a rapid increase in blood glucose and plasma IRI levels, while GH concentrations showed a less marked and more delayed increase and plasma FFA showed a clear downtrend. Somatostatin infusion suppressed the GH and IRI release induced by DBC, potentiated its hyperglycemic effect and changed the pattern of FFA. These results suggest that somatostatin inhibits hormone secretion distal to the generation of cyclic AMP.

Adult↗
PubMed1976

to luteinizing.

The effect of luteinizing hormone-releasing hormone (LHRH) on plasma prolactin (PRL) was studied in eight acromegalic patients. After LHRH injection a significant increase in plasma prolactin levels was obtained in three of them. This non specific prolactin response to LHRH represents an additional proof of the well known abnormalities of pituitary hormone response to various stimuli in acromegaly.

Acromegaly↗
PubMed1976

Hyperthyroidism with elevated plasma TSH levels and pituitary tumor: study with somatostatin.

In a 51-year-old man with hyperthyroidism, elevated plasma TSH levels, and evidence of pituitary tumor, plasma TSH levels decreased from a mean basal value of 11 muU/ml to 6 mu/u/ml during the infusion of 200 mug of somatostatin in 60 min. Thyrotropin releasing factor failed to increase plasma TSH levels. T3 administration failed to supress significantly the elevated thyroid 131I uptake. During T3 administration plasma TSH levels showed a downtrend but were not clearly suppressed. These findings are discussed in light of the pertinent literature.

Humans↗
PubMed1976

Pituitary hormone responses to hypothalamic releasing hormones in acromegaly.

The pituitary reserve of GH, prolactin, TSH, LH, and FSH has been studied in a group of 13 acromegalic patients with the aim of evaluating the pituitary function and the activity of the disease. Plasma GH, TSH and polactin were determined after thyrotrophin releasing hormone (TRH) administration, plasma gonadotrophins and GH after luteinizing hormone releasing hormone (LH-RH) administration. The plasma TSH response to TRH was generally blunted in the patients treated with pituitary irradiation; however, none of the patients with diminished TSH reserve had signs of hypothyroidism. Six acromegalics showed prolactin basal levels higher than controls; none had galactorrhoea; 4 of them complained of impairment of the gonadal function. The prolactin response to TRH was variable and not related to prolactin basal levels. A subnormal LH reserve after LH-RH stimulation was observed in 5 out of 10 patients; 4 of them had also clinical signs of hypogonadism. A normal FSH response to LH-RH was present in all patients. A non-specific GH response to TRH and/or LH--RH was obtained in about half of the acromegalics studied. The GH responsiveness to TRH and/or LH-RH was not related to the activity of the disease or to a specific derangement of the hypothalamo-pituitary function. A concordant response was observed only between GH and prolactin response to TRH; the highest prolactin responses to TRH were obtained in the GH responsive patients. Each patient showed a constant GH pattern of response on repeated testing. Even after pituitary irradiation the pattern of GH response was unchanged in spite of lowered GH plasma levels.

Acromegaly↗
PubMed1975

Dose-response study of the inhibiting effect of somatostatin on growth hormone and insulin secretion in normal subjects and acromegalic patients.

A dose-response study of the effect of somatostatin on plasma growth hormone (GH) and immunoreactive insulin (IRI) levels was performed in normal subjects and acromegalic patients. In normal subjects 150 mug of somatostatin completly suppressed GH and IRI responses to arginine, while with 75 and 37.5 mug only a partial suppression was usually observed. Basal levels of plasma IRI were significantly lowered within 15 min from the start of somatostatin injection at each of the three dose levels. In three acromegalics the doses of 150 and 75 mug of somatostatin were effective in lowering both GH and IRI levels; the dose of 37.5 mug was still effective in lowering plasma IRI levels, while GH levels were not significantly modified. A dose of somatostatin inhibiting GH secretion without affecting insulin secretion has not been found either in acromegalics and in normals. It was concluded that the effects of somatostatin on GH and IRI secretion cannot be easily dissociated.

Acromegaly↗